Suppr超能文献

非处方奥美拉唑的疗效与安全性

[Efficacy and safety of OTC omeprazole].

作者信息

Labenz J, Willmer C

机构信息

Diakonie Klinikum jung-stilling, Siegen.

出版信息

MMW Fortschr Med. 2012 Dec 17;154 Suppl 4:110-4.

Abstract

BACKGROUND

Heartburn and acid regurgitation--cardinal symptoms of gastro-esophageal reflux disease (GERD)--rank among the most frequent gastrointestinal disorders. The high degree of suffering often requires a fast and effective symptom relief. Proton pump inhibitors (PPI) are the medication of choice for all manifestations of GERD. Since 2009 the PPI omeprazole is available for OTC-treatment (over the counter). The aim of this pharmacoepidemiologic observational study was to document efficacy and safety of omeprazole under daily-life conditions of self-medication. 2718 patients who had bought the omeprazole product Antra in the pharmacy for treatment of heartburn or acid regurgitation participated in this prospective non-interventional study.

RESULTS

A large part of patients benefited from the PPI-treatment with fast and long lasting symptom relief: 44% of patients already experienced improvement of their symptoms within two to four hours, 71% of patients were completely symptom-free after the OTC treatment (max. 14 days). Overall the PPI was very well tolerated. Adverse events were rare (2.4%) and in accordance with previous experiences. 94% of patients indicated that in case of need they would take the product again. 40% of 178 patients who had been followed-up over a period of three months remained completely symptom-free.

CONCLUSION

The efficacy and safety of omeprazole known from clinical trials are confirmed for OTC-treatment under daily-life conditions by the results of this non-interventional study.

摘要

背景

烧心和反酸——胃食管反流病(GERD)的主要症状——是最常见的胃肠道疾病之一。严重的不适常常需要快速有效的症状缓解。质子泵抑制剂(PPI)是治疗GERD所有表现形式的首选药物。自2009年起,PPI奥美拉唑可用于非处方治疗。这项药物流行病学观察性研究的目的是记录奥美拉唑在自我用药的日常生活条件下的疗效和安全性。2718名在药店购买奥美拉唑产品安特拉用于治疗烧心或反酸的患者参与了这项前瞻性非干预性研究。

结果

大部分患者从PPI治疗中受益,症状得到快速且持久的缓解:44%的患者在两到四小时内症状即有所改善,71%的患者在非处方治疗后(最长14天)完全没有症状。总体而言,PPI耐受性良好。不良事件很少见(2.4%),且与以往经验相符。94%的患者表示如有需要会再次服用该产品。在178名接受了三个月随访的患者中,40%的患者仍然完全没有症状。

结论

这项非干预性研究的结果证实,在日常生活条件下进行非处方治疗时,奥美拉唑的疗效和安全性与临床试验中已知的情况一致。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验